Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous ketamine for major depressive disorder in older adults
ACTRN12617001130358Phase 2Withdrawn
- Sponsor
- University of Otago
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by University of Otago. Primary endpoint: Change in Geriatric Depression Scale score. Planned start Sep 2018; status: withdrawn.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12617001130358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001130358.